Scotland rejects five products for use in the region's NHS
This article was originally published in Scrip
The Scottish Medicines Consortium declined to recommend five products for use in the region's national health service earlier this month, including GlaxoSmithKline's anticancer Tyverb (lapatinib) and Tibotec's (Janssen-Cilag) AIDS drug Intelence (etravirine).
You may also be interested in...
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.